SECOND AMENDMENT TO PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • March 25th, 2009 • Ceragenix Pharmaceuticals, Inc. • Surgical & medical instruments & apparatus
This agreement is entered into this day of March 2009 by and between Osmotics Corporation (“Osmotics”) and Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (collectively the “Parties”).
THIRD AMENDMENT to the EXCLUSIVE LICENSE BETWEEN BRIGHAM YOUNG UNIVERSITY AND CERAGENIX PHARMACEUTICALS, INC.Exclusive License Agreement • March 25th, 2009 • Ceragenix Pharmaceuticals, Inc. • Surgical & medical instruments & apparatus
This Third Amendment is effective October 21, 2008, and amends the Exclusive License Agreement (hereinafter “Original Agreement”) for Steroid-Derived Antibiotics technology that became effective May 1, 2004, by and between Brigham Young University, a Utah non-profit corporation and institution of higher education, with its principal campus and place of business located at Provo, Utah 84602 (referred to herein as “BYU”) and Osmotics Corporation, who subsequently transferred responsibility for this license to Ceragenix Pharmaceuticals, Inc., (a subsidiary of the corporation formerly known as Osmotics Corporation) a Colorado corporation with its principal place of business located at 1444 Wazee Street, Suite 210, Denver, Colorado 80202 (referred to herein as “Ceragenix” or “LICENSEE”).
